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http://dx.doi.org/10.1016/j.jaci.2016.01.011randomized to receive 5 mg (2 puffs of 2.5 mg) or 2.5 mg (2 puffs
of 1.25 mg) of once-daily tiotropium or placebo (2 puffs)
administered through the Respimat device every evening, each
as add-on treatment to ICS background therapy, with or
without a leukotriene receptor antagonist; long-acting
b2-agonist therapy was not permitted during the study.
Results: Improvement in peak FEV1 within 3 hours after dosing
at 24 weeks (primary end point) was statistically significant with
both tiotropium doses compared with placebo: 5 mg of
tiotropium, 174 mL (95% CI, 76-272 mL); 2.5 mg of tiotropium,
134 mL (95% CI, 34-234 mL). Significant improvements in
trough FEV1 at week 24 (a secondary end point) were observed
with the 5-mg dose only. Trends for improvement in asthma
control and health-related quality of life over the 48-week
treatment period were observed.
Conclusions: Once-daily tiotropium significantly improved lung
function and was safe and well tolerated when added to at least
ICS maintenance therapy in adolescent patients with moderate
symptomaticasthma.Largerresponseswereobservedwith the5-mg
tiotropium dose. (J Allergy Clin Immunol 2016;138:441-50.)
Key words: Adolescent, anticholinergic drug, asthma, asthma
control, efficacy, FEV1, lung function, Respimat, safety, tiotropium
Asthma is a heterogeneous condition characterized by chronic
airway inflammation and intermittent symptoms that affects
approximately 300 million persons worldwide1 and is the most
prevalent chronic disease in children and adolescents.2 At least
40% of patients experience asthma symptoms and exacerbations
despite treatment with inhaled corticosteroids (ICSs) adminis-
tered as monotherapy or in combination with a long-acting
b2-agonist (LABA).
3-5 Frequent exacerbations contribute to
high treatment costs and are associated with an increased risk
of persistent asthma in children.6,7 Therefore, limiting the rate
of exacerbations and achieving asthma control are the main goals
of asthma treatment, especially in this age group.
As in adults, ICSs are viewed as the most efficacious first-line
therapy and are recommended for adolescents with persistent
asthma, with other controllers added in a stepwise manner if
patients continue to experience symptoms or asthma exacerba-
tions.1,8 Clinical studies in adults have demonstrated that
tiotropium administered through the Respimat Soft Mist inhaler
(Boehringer Ingelheim, Ingelheim am Rhein, Germany) is an
effective and well-tolerated add-on treatment to at least ICS
maintenance therapy in patients with mild, moderate, or severe
symptomatic asthma.9-16 The 2015 revision of the Global Initia-
tive for Asthma strategy includes 5mg of tiotropium administered441
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442 HAMELMANN ET ALAbbreviations usedACQ-6: 6-question Asthma Control QuestionnaireACQ-7: 7-question Asthma Control QuestionnaireAQLQ(S)112: Asthma Quality of Life Questionnaire with
Standardized Activities (>_12 years)AUC: Area under the curveAUC(0-3h): Area under the curve within 3 hours after dosingFVC: Forced vital capacityFVC(0-3h): Forced vital capacity within 3 hours after dosingICS: Inhaled corticosteroidLABA: Long-acting b2-agonistLTRA: Leukotriene receptor antagonistPEF: Peak expiratory flowthrough the Respimat device as an option for addition to ICS plus
a LABA treatment at steps 4 and 5 in adults with a history of
exacerbations.1 Phase II studies in adolescents and children have
shown similar lung function benefits to those observed in adults
when tiotropium Respimat is added to at least ICSs.17,18
We present results from a 1-year phase III study designed to
examine the efficacy and safety of 2 doses (5 and 2.5 mg) of once-
daily tiotropium Respimat compared with placebo when added to
background treatment with ICS maintenance therapy with or
without a leukotriene receptor antagonist (LTRA) in adolescents
with moderate symptomatic asthma.
METHODS
Study design
This was a 1-year, phase III, randomized, double-blind, placebo-controlled,
parallel-group study (NCT01257230) in adolescent patients (aged
12-17 years) with moderate symptomatic asthma. The trial was conducted
at 65 sites in 12 countries (Germany, Spain, Hungary, Italy, Slovakia, Latvia,
Ukraine, Russia, Korea, Mexico, Chile, and the United States).
Population
Eligible patients were aged 12 to 17 years with a documented history of
asthma of more than 3 months at enrollment and were symptomatic at
screening and before randomization, which was defined as a 7-question
Asthma Control Questionnaire (ACQ-7) mean score of at least 1.5. Patients
were required: to have been receiving maintenance therapy with ICSs with or
without a LABA or an LTRA for 4 or more weeks before screening; to have a
prebronchodilator FEV1 of 60% to 90% of predicted normal value at
screening, FEV1 reversibility of 12% or greater and 200 mL or greater 15 to
30 minutes after 400 mg of salbutamol (albuterol), and variability of absolute
FEV1 values from screening to randomization within 630%; and never to
have smoked or to have stopped smoking 1 or more years before enrollment
(parental smoking was also recorded).
A key exclusion criterion was a diagnosis of any significant lung disease
other than asthma.
Procedures
After a 4-week screening period, patients were randomized in a 1:1:1 ratio
to receive 5 mg (2 puffs of 2.5 mg) or 2.5 mg (2 puffs of 1.25 mg) of once-daily
tiotropium or placebo (2 puffs) in the evening (between 5 and 7 PM) delivered
through theRespimat SoftMist inhaler (Boehringer Ingelheim) over 48weeks.
Patients were followed up for a further 21 days to assess safety (see Fig E1 in
this article’s Online Repository at www.jacionline.org). Randomization was
performed with a pseudo-random number generator with a supplied seed
number and fixed block sequence, with a block size of 6.Study treatment (tiotropium or placebo) was taken as add-on therapy to
background ICS maintenance treatment with or without an LTRA. Permitted
doses of ICS maintenance therapy were 200 to 800 mg of budesonide or
equivalent for patients aged 12 to 14 years and 400 to 800 mg of budesonide or
equivalent for patients aged 15 to 17 years. Thesewere continued unaltered for
the duration of the study. Patients were required to stop LABA therapy at least
72 hours before screening (visit 1) but were permitted to continue LTRAs at
the same dose throughout the study. Open-label salbutamol (albuterol)
hydrofluoroalkane metered-dose inhalers (100 mg per actuation) were
provided as rescue medication during the screening and treatment periods.
The study compliedwith the principles of theDeclaration ofHelsinki and the
International Conference on Harmonisation for Good Clinical Practice Guide-
lines. The trial protocol, patient information sheet, and consent form were
reviewed and approved by each participating institution’s review board. Before
participation in the study, written, informed consent was obtained from each
patient and the patients’ parents or guardians, according to local requirements.Analysis
The primary efficacy end point was change from baseline (response) in
peak FEV1 within 3 hours after dosing (peak FEV1[0-3h]) at week 24. Blinded
efficacy and safety monitoring continued to week 48.
Secondary end points included trough FEV1 (measured at the end of the
dosing interval at 10 minutes before administration of the next dose of study
medication), FEV1 area under the curve (AUC) within 3 hours after dosing
(FEV1 AUC[0-3h]), peak forced vital capacity (FVC) within 3 hours after
dosing (FVC[0-3h]), trough FVC, FVC AUC(0-3h), and mean forced expiratory
flow between 25% and 75% of FVC, all measured after 24 weeks of treatment.
Other secondary efficacy end points included time to first episode of asthma
worsening (prespecified as exacerbation) and time to first severe asthma
exacerbation evaluated over the 48-week treatment period. An episode of
asthma worsening was defined as a progressive increase in 1 or more asthma
symptoms that were outside a patient’s usual day-to-day variation and lasting
for 2 ormore consecutive days and/or a decrease in a patient’s bestmorningpeak
expiratory flow (PEF) of 30% or more from their mean morning PEF for 2 or
more consecutive days; these were recorded as described below. A severe
asthma exacerbation was defined as an episode of asthma worsening that
required treatmentwith systemic corticosteroids for 3 ormore consecutive days.
The number of puffs of rescue medication during the daytime, nighttime,
and entire 24-hour period was measured by the patients at home by using the
AM3 asthma monitor device (electronic peak flow meter and eDiary;
eResearch Technology, H€ochberg, Germany) and expressed as mean weekly
values. Asthma control was assessed by using the 6-question Asthma Control
Questionnaire (ACQ-6) and ACQ-7 and expressed as a responder rate after
24 weeks of treatment. Patients were classified as responders if they achieved
the minimal clinically important difference of a 0.5-point or greater reduction
in ACQ scores.19 For completeness of data, post hoc analyses of ACQ-6 and
ACQ-7 scores at week 48 were also performed.
Additional end points included the Asthma Quality of Life Questionnaire
with Standardized Activities (>_12 years; AQLQ[S]112) total score and
responder rate after both 24 and 48weeks of treatment. Patients were classified
as responders if they reached the minimal clinically important difference of an
increase from baseline of 0.5 points or more.20Weekly mean predose morning
and evening PEF responses were measured with the AM3 device.
Post hoc analyses of peak and trough FEV1 at week 24 were performed in
patients aged 12 to 14 years and 15 to 17 years to determinewhether responses
in lung function after tiotropium add-on therapy differed significantly between
patients in early and late adolescence.
Adverse events were monitored throughout the treatment and follow-up
periods to assess safety and tolerability.Statistical analyses
Efficacy analyses were performed on the full analysis set, which was the
same as the treated set. Safety analyses were performed on the treated set,
which was defined as all randomized patients who had received at least 1 dose
of study medication.
Discontinued treatment
(n = 6; 4.3%)
–  Worsening of
 disease under study
 (n = 2; 1.4%)
–  Not compliant with
 protocol (n = 3; 2.2%)
–  Other (n = 1; 0.7%)
Discontinued treatment
(n = 10; 8.0%)
–  Lack of efficacy
 (n = 1; 0.8%)
–  Consent withdrawn
 not because of AE
    (n = 4; 3.2%)
–  Other (n = 5; 4.0%)
Discontinued treatment
(n = 5; 3.7%)
–  Not compliant with
 protocol (n = 1; 0.7%)
–  Consent withdrawn
 not because of AE
    (n = 1; 0.7%)
–  Other (n = 3; 2.2%)
Completed
(n = 376; 94.7%)
Patients randomized
(n = 398)
Patients enrolled
(n = 673)
Placebo Respimat® 
QD (n = 138)
Treated set (n = 138)
Full analysis set (n = 138)
Tiotropium Respimat®
2.5 μg QD (n = 125)
Treated set (n = 125)
Full analysis set (n = 125)
Tiotropium Respimat®
5 μg QD (n = 135)
Treated set (n = 134)
Full analysis set (n = 134)
Patients excluded
(n = 275)
FIG 1. CONSORT diagram. Of the patients screened, the main reasons for noninclusion were as follows:
adverse event (n5 3), consent withdrawn (n5 11), violation of inclusion or exclusion criteria (n5 243), lost
to follow-up (n 5 3), and other (n 5 15). Of those randomized, 1 patient randomized to 5 mg of tiotropium
administered through the Respimat device was not treated. AE, Adverse event; QD, once daily.
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probability of a type I error (1-sided a5 .025). First, the superiority of 5mg of
tiotropium versus placebo for peak FEV1(0-3h) response at week 24 was tested.
If the corresponding null hypothesis was rejected, the same null hypothesis for
the 2.5-mg dose was tested. If the superiority of treatment with 5 mg of
tiotropium over placebo could not be established, testing of the second
hypothesis was considered descriptive only.
The primary end point, peak FEV1(0-3h) response, was analyzed by using a
restricted maximum likelihood-based mixed-effects model with repeated
measures. The model included the fixed, categorical effects of ‘‘treatment,’’
‘‘country,’’ ‘‘visit,’’ and ‘‘treatment-by-visit interaction,’’ as well as the
covariates of ‘‘baseline value’’ and ‘‘baseline value-by-visit interaction.’’
‘‘Patient’’ was included as a random effect in the model. Adjusted means
and treatment contrasts were calculated, together with 95% CIs and 2-sided
P values. The level of significance was set to .05.
All continuous secondary end points were analyzed by using a maximum
likelihood-based mixed-effects model with repeated measures. Adjusted
mean values and treatment contrasts were calculated, together with 95%
CIs. All calculated P values were to serve an exploratory function. There was
no adjustment for multiplicity, and all analyses were evaluated at an a level of
.05. For time to first severe exacerbation and time to first episode of asthmaworsening, analyses were to be performed with the Cox proportional hazards
regression model, with ‘‘treatment’’ fitted as an effect.
Sample-size calculations determined that 127 patients per treatment group
were required to detect a difference of 120 mL between treatments in the
change from baseline of peak FEV1(0-3h) with a power of approximately 80%,
assuming a common SD of 340 mL.
For lung function end points, baseline (visit 2; randomization) was
defined as the respective pretreatment value measured 10 minutes before
administration of the first dose of study medication.
RESULTS
A total of 398 patients were randomized. Of these, 376 (94.7%)
patients completed the 48-week treatment period and 21 (5.3%)
prematurely discontinued study medication (Fig 1).
Baseline patient demographics and disease
characteristics
Overall, baseline patient demographics were balanced across
treatment groups (Table I). There were more male patients
TABLE I. Baseline patient demographics and disease characteristics
Tiotropium Respimat
5 mg QD (n 5 134)
Tiotropium Respimat
2.5 mg QD (n 5 125)
Placebo Respimat
QD (n 5 138)
Age (y)* 14.5 6 1.6 14.2 6 1.8 14.2 6 1.7
Age (y), no. (%)
<12 0 1 (0.8) 0
12-14 67 (50.0) 72 (57.6) 76 (55.1)
15-17 67 (50.0) 52 (41.6) 62 (44.9)
Sex, no. (%)
Male 89 (66.4) 81 (64.8) 88 (63.8)
Body mass index (kg/m2)* 21.6 6 4.0 21.9 6 5.1 20.6 6 3.5
Smoking status, no. (%)
Never smoked 134 (100) 125 (100) 137 (99.3)
Current smoker 0 0 1 (0.7)
Exposure to second-hand smoke, no. (%)
No 118 (88.1) 115 (92.0) 120 (87.0)
Yes 16 (11.9) 10 (8.0) 18 (13.0)
Duration of asthma (y)* 8.2 6 4.2 7.7 6 4.0 7.7 6 4.2
Prebronchodilator FEV1 at screening*
Actual (mL) 2624 6 593 2537 6 552 2553 6 616
Percent predicted 77.3 6 8.6 78.1 6 7.9 77.6 6 7.5
Postbronchodilator FEV1 at screening*
Actual (mL) 3313 6 738 3200 6 670 3210 6 754
Percent predicted 97.6 6 11.1 98.7 6 10.5 97.7 6 9.7
FEV1*
Actual (mL) 2821 6 665 2680 6 629 2736 6 686
Percent predicted 83.0 6 11.2 82.3 6 10.3 83.0 6 10.2
FVC*
Actual (mL) 3639 6 902 3461 6 835 3570 6 845
Percent predicted 93.4 6 14.4 92.6 6 12.8 95.0 6 12.7
FEV1/FVC ratio (%)* 78.5 6 10.4 78.4 6 11.3 76.9 6 9.7
FEF(25-75%) (L/s)* 2.6 6 1.0 2.4 6 0.9 2.4 6 1.0
Predose morning PEF (L/min)* 341.2 6 87.4 343.6 6 93.9 334.6 6 93.4
Predose evening PEF (L/min)* 362.6 6 86.0 360.7 6 91.3 356.7 6 96.1
ACQ-6 score* 2.0 6 0.4 2.0 6 0.5 2.0 6 0.5
ACQ-7 score* 2.0 6 0.4 2.1 6 0.5 2.0 6 0.4
AQLQ(S)112 score* 5.3 6 0.8 5.4 6 0.9 5.4 6 0.8
ICS dose of stable maintenance treatment (mg)* 536 6 256 557 6 346 527 6 275
Concomitant therapies in the 3 mo before screening, no. (%)
LABA 41 (30.6) 35 (28.0) 39 (28.3)
LTRA 17 (12.7) 12 (9.6) 18 (13.0)
Concomitant therapies during the treatment period, no. (%)
LABA 4 (3.0) 0 7 (5.1)
LTRA 15 (11.2) 8 (6.4) 14 (10.1)
The treated set is shown.
FEF(25-75%), Forced expiratory flow between 25% and 75% of FVC.
*Values are means 6 SD.
Assigned as an important protocol violation.
Budesonide or equivalent dose.
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14.3 years (54.2% aged 12-14 years and 45.6% aged 15-17 years;
1 patient was aged 11 years at enrollment) with amean duration of
asthma of 7.9 years, and 11.1% of patients reported passive expo-
sure to smoke. In the 3 months before screening, all patients had
received maintenance treatment with ICSs, 29.0% had received a
LABA, and 11.8% had received an LTRA. During the treatment
period, 2.8% of patients received treatment with a LABA (proto-
col violations) and 9.3% continued treatment with an LTRA.Efficacy
Primary end point. A statistically significant greater
improvement in peak FEV1(0-3h) response was observed after24 weeks with both doses of tiotropium versus placebo (Fig 2).
The adjusted mean difference in response was greater with the
5-mg dose (174 mL [95% CI, 76-272 mL] vs 134 mL [95% CI,
34-234 mL] for the 2.5-mg dose).
Post hoc analyses demonstrated that improvements in peak
FEV1(0-3h) were similar in both younger (12-14 years) and older
(15-17 years) patients (treatment-by-subgroup interaction
P value 5 .21). This response was numerically higher but not
statistically significant with 2.5 mg of tiotropium in the 15- to
17-year age group (see Table E1 in this article’s Online
Repository at www.jacionline.org).
Secondary end points. A statistically significant improve-
ment in trough FEV1 versus placebo was observed for 5 mg of
tiotropium (Table II). Post hoc analyses confirmed that
(n = 120)
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FIG 2. Peak FEV1(0-3h) response at week 24: full analysis set. Results are
adjusted for treatment, country, week, baseline, treatment-by-week interac-
tion, and baseline-by-week interaction. Error bars are 6 SEs. Common
baseline mean FEV16 SD is 27476 662mL. **P < .01 versus placebo Respi-
mat and ***P < .001 versus placebo Respimat. Peak FEV1(0-3h), Peak FEV1
within 3 hours after dosing; QD, once daily.
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 2
HAMELMANN ET AL 445improvements in trough FEV1 were independent of age group
(treatment-by-subgroup interaction P value 5 .70; see Table E2
in this article’s Online Repository at www.jacionline.org).
AUC calculations provide a useful method to demonstrate an
average bronchodilatory effect over time. Improvements in FEV1
AUC(0-3h) for both the 5- and 2.5-mg doses compared with placebo
were statistically significant (Table II), but the numerically higher
values for peak FVC(0-3h), trough FVC, and FVC AUC(0-3h) with
both tiotropium doses versus placebo did not reach statistical
significance (see Table E3 in this article’s Online Repository at
www.jacionline.org).
Forced expiratory flow between 25% and 75% of FVC
treatment differences were statistically significant at all time
points with both tiotropium doses compared with placebo, with
the exception of 2.5 mg of tiotropium at 10 minutes before dosing
and 30 minutes after dosing (Fig 3).
Overall, 16 patients experienced at least 1 severe asthma
exacerbation during the study: 2 (1.5%) in the 5 mg of tiotropium
group, 5 (4.0%) in the 2.5mg of tiotropium group, and 9 (6.5%) in
the placebo group. At least 1 episode of asthma worsening was
reported for 30 (22.4%) patients in the 5 mg of tiotropium group,
34 (27.2%) in the 2.5 mg of tiotropium group, and 37 (26.8%) in
the placebo group. The median time to first severe asthma
exacerbation and time to first episode of asthma worsening
were not calculated because events were reported for less than
50% of patients in each treatment group.
The weekly mean number of puffs of rescue medication used
during the daytime, nighttime, and entire 24-hour period
decreased over the 48-week treatment period but was statistically
significant only with the 2.5-mg dose during the entire 24-hour
period at week 48 (see Table E4 in this article’s Online Repository
at www.jacionline.org).
Adjusted mean ACQ-6 and ACQ-7 scores at week 24 in
patients treated with tiotropium were numerically lower than
those in patients treated with placebo: 20.054 (95% CI, 20.235
to 0.127) and 20.097 (95% CI, 20.263 to 0.069) points,
respectively, with 5 mg of tiotropium and 20.147 (95% CI,
20.333 to 0.038) and20.160 (95% CI,20.330 to 0.010) points,
respectively, with 2.5mg of tiotropium. The proportion of patients
who achieved theminimal clinically important difference for both
the ACQ-6 and ACQ-7 was higher with both tiotropium doses at
week 24 compared with placebo, but the differences were notstatistically significant (ACQ-6, Wilcoxon rank sum test: P5 .51
for 5 mg of tiotropium and P 5 .14 for 2.5 mg of tiotropium;
ACQ-7, Wilcoxon rank sum test: P 5 .12 for 5 mg of tiotropium
and P 5 .08 for 2.5 mg of tiotropium; see Fig E2 in this article’s
Online Repository at www.jacionline.org).
Post hoc analyses at week 48 demonstrated further improve-
ments (score reductions) in adjusted mean ACQ-6 and ACQ-7
scores (adjusted mean compared with placebo: 20.079 and
20.127, respectively, for 5 mg of tiotropium and 20.162 and
20.191, respectively, for 2.5 mg of tiotropium). The proportion
of patients who were responders increased between weeks 24
and 48 for both the ACQ-6 (Wilcoxon rank sum test: P 5 .40
for 5 mg of tiotropium and P 5 .28 for 2.5 mg of tiotropium vs
placebo at week 48) and ACQ-7 (Wilcoxon rank sum test:
P 5 .17 for 5 mg of tiotropium and P 5 .04 for 2.5 mg of
tiotropium vs placebo at week 48) and was higher in the 2
tiotropium treatment groups (see Fig E2).
Additional end points. The adjusted mean AQLQ(S)112
score improved during the 48-week treatment period in all 3
treatment groups, but the treatment differences were not statis-
tically significant between either tiotropium dose and placebo at
week 24 or 48 (0.079 [95% CI,20.087 to 0.245] and 0.030 [95%
CI, 20.138 to 0.198], respectively, for 5 mg of tiotropium and
0.135 [95% CI, 20.036 to 0.306] and 0.140 [95% CI, 20.034 to
0.314], respectively, for 2.5 mg of tiotropium). The proportion of
patients whowere responders increased between weeks 24 and 48
in all 3 treatment groups and was highest in the 5mg of tiotropium
group (Wilcoxon rank sum test:P5.02 for 5mg of tiotropium and
P5.17 for 2.5mg of tiotropium vs placebo at week 24;P5.15 for
5mg of tiotropium andP5.58 for 2.5mg of tiotropium vs placebo
at week 48; Fig 4).
Predose morning and evening PEF responses (analyzed as
weekly means) tended to be larger in the 5mg of tiotropium group
compared with those in the 2.5 mg of tiotropium group and were
higher in both tiotropium treatment groups than in the placebo
group. Over the 48-week treatment period, the differences in
adjusted mean predose morning and evening PEF responses
between 5 mg of tiotropium and placebo were statistically
significant at almost all weeks, including week 24 (P 5 .02 and
P 5 .01 for predose morning and evening PEF, respectively)
and week 48 (P 5 .005 and P 5 .008 for predose morning and
evening PEF, respectively). However, in the 2.5 mg of tiotropium
treatment group, statistical significance in the weekly mean
difference from placebo was less consistent and observed at
some weeks only (week 24: P 5 .17 and P 5 .08 for predose
morning and evening PEF, respectively; week 48: P 5 .0504
and P 5 .03 for predose morning and evening PEF, respectively;
Fig 5 and see Fig E3 in this article’s Online Repository at
www.jacionline.org).Safety and tolerability
The overall incidence of adverse events was comparable across
the 3 treatment groups (Table III). There was a low incidence of
drug-related adverse events, and most adverse events were mild
or moderate in intensity. Serious adverse events, none of which
was considered drug-related, were reported for 7 patients: 3
(2.2%) receiving 5 mg of tiotropium (1 patient with an asthma
exacerbation, 1 with upper abdominal pain, and 1 with an
anaphylactic reaction after a plant sting), 2 (1.6%) receiving
2.5 mg of tiotropium (1 patient with multiple injuries after an
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FIG 3. Forced expiratory flow between 25% and 75% of FVC (FEF[25-75%]) response at week 24: full analysis
set. Results are adjusted for treatment, country, week, baseline, treatment-by-week interaction, and
baseline-by-week interaction. Common baseline mean 6 SD is 2.48 6 0.97 L/s. *P < .05 versus placebo Re-
spimat, **P < .01 versus placebo Respimat, and ***P < .001 versus placebo Respimat. QD, Once daily.
TABLE II. Secondary FEV1 efficacy end point responses at week 24
Treatment and parameter
Adjusted
mean 6 SE (mL)
Active versus placebo Respimat
Adjusted mean of
difference 6 SE (mL) 95% CI P value
Trough FEV1 (mL)
Tiotropium Respimat 5 mg QD (n 5 131) 400 6 41 117 6 54 10 to 223 .03
Tiotropium Respimat 2.5 mg QD (n 5 119) 367 6 44 84 6 56 225 to 194 .13
Placebo Respimat QD (n 5 137) 283 6 40
FEV1 AUC(0-3h) (mL)
Tiotropium Respimat 5 mg QD (n 5 131) 463 6 36 181 6 48 88 to 275 <.001
Tiotropium Respimat 2.5 mg QD (n 5 119) 411 6 38 130 6 49 34 to 225 .008
Placebo Respimat QD (n 5 137) 281 6 35
The full analysis set is shown. Results are adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. The common baseline
mean FEV1 6 SD is 2747 6 662 mL.
QD, Once daily.
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(1 patient with gastroenteritis and 1with teratoma). Therewere no
deaths during the study.DISCUSSION
This phase III study examining the efficacy and safety of
addition of 5 and 2.5 mg of tiotropium to background treatment
with ICSs with or without an LTRA in adolescent patients with
moderate symptomatic asthma confirms that the addition of
tiotropium provides significant improvements in lung function.
These results are consistent with the improvements in lung
function observed in previously published phase II studies in
adolescents17 and phase III studies in adults13,21 with moderate
symptomatic asthma. Improvements in asthma control, measured
based on ACQ-6 and ACQ-7 scores, were positive but not statis-
tically significant. Overall, the efficacy improvements confirmed
consistently greater benefit with the 5-mg dose of tiotropium,
which is in line with previously reported dose ordering in adultphase II dose-ranging studies.10,12 Safety and tolerability were
comparable with those of background therapy during this
relatively large 48-week study, which is consistent with
previously published data in adults and adolescents.
The primary lung function end point at week 24 was met, and
the continued blinded assessment up to 48 weeks demonstrated
that these improvements were sustained. Weekly predose PEF
responses followed a similar pattern. Although there is no
established minimum clinically important difference for FEV1
responses, the observed effect sizes are comparable with those
seen with LABAs and in other studies of tiotropium in asthmatic
patients, in which improvements in clinically relevant measures
of asthma control were also observed.13,22 Therefore, the
bronchodilatory effects of tiotropiummight manifest in improved
asthma control, and achieving and maintaining improved lung
function is important, particularly in the adolescent age group,
because reduced lung function can be a marker associated with
increased risk of future asthma exacerbations and reduced asthma
control.23-25 Over the 48-week treatment period, the incidences of
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HAMELMANN ET AL 447severe exacerbations and episodes of asthma worsening were
relatively low, which was not unexpected because this patient
population had moderate asthma, which is not associated with a
high rate of exacerbations. Improvements in ACQ-6, ACQ-7,
and AQLQ(S)112 scores were observed but were not statistically
significant compared with those in patients receiving placebo;
however, the study was not powered for these end points. Further-
more, in a network analysis of results from a large number of
asthma trials in which ACQ and AQLQ scores were assessed,
Bateman et al26 reported that the minimal clinically important
difference (expressed as mean improvements between treatment
arms) is seldom achieved and unlikely in studies like ours, in
which a second or third controller is added in combination with
ICSs.
A limitation of our study might be the relatively large response
observed in the placebo group. Outside of the clinical trial
environment, adherence to asthma treatment in the adolescentpopulation is notably poor.27-29 It is likely that patients became
more adherent to background ICS therapy during the course of
the trial, a well-known phenomenon in clinical trials in this age
group.26
The results of our study add to the body of evidence that
supports the inclusion of tiotropium as an option in the stepwise
addition of treatment for uncontrolled asthma in adolescents.
According to current guidelines, the addition of a LABA should
be considered in adolescent patients with mild or moderate
asthma not fully controlled by ICS monotherapy, with a higher
dose of ICS or the addition of an LTRA as acceptable
alternatives.1 Studies comparing the responses of individual
patients to long-acting anticholinergic bronchodilators and
LABAs confirm marked heterogeneity, with similar proportions
of patients demonstrating response or nonresponse to both
therapeutic options.9,13,21 Consistent with this observation, a
crossover study performed in 182 children with uncontrolled
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FIG 5. Adjusted mean predose morning (A) and evening (B) PEF responses at weeks 24 and 48: full analysis
set. Results are adjusted for treatment, country, week, baseline, treatment-by-week interaction, and
baseline-by-week interaction. Common baseline mean predose morning PEF 6 SD is 339.7 6 91.5 L/min;
common baseline predose evening PEF 6 SD is 359.9 6 91.1 L/min. Adjusted mean predose morning
and evening PEF responses versus placebo were as follows: 5 mg of tiotropium, P5 .02 and P5 .01, respec-
tively, at week 24 and P 5 .005 and P 5 .008, respectively, at week 48; 2.5 mg of tiotropium, P 5 .17 and
P5 .08, respectively, at week 24 and P5 .0504 and P5 .03, respectively, at week 48. *P < .05 versus placebo
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(a higher dose of ICS or addition of a LABA or an LTRA) in
98% of patients, supporting the need for different treatment
options for the management of asthma in children.8 Circum-
stances in which tiotropium might be favored include when
a LABA or other controllers do not achieve the desired
improvements, when tolerance against the bronchoprotectiveeffect of a LABA is suspected, or where there are safety concerns
about treatment with LABAs.30,31 The positive effect of
combining tiotropium with LABAs in patients with severe
symptomatic asthma has been confirmed in studies in adults.11
Results from similar studies in adolescents and children have
been completed (NCT01277523 and NCT01634152), and
publication of these results is anticipated.
TABLE III. Overall summary of adverse events
Tiotropium Respimat
5 mg QD (n 5 134)
Tiotropium Respimat
2.5 mg QD (n 5 125)
Placebo Respimat
QD (n 5 138)
Patients with any AE 84 (62.7) 79 (63.2) 82 (59.4)
Patients with severe AEs 2 (1.5) 2 (1.6) 3 (2.2)
Patients with investigator-defined drug-related AEs 4 (3.0) 1 (0.8) 1 (0.7)
Patients with AEs leading to discontinuation of study medication 0 0 2 (1.4)
Patients with serious AEs 3 (2.2) 2 (1.6) 2 (1.4)
AEs in >5% patients by preferred term*
Asthma 23 (17.2) 27 (21.6) 32 (23.2)
Nasopharyngitis 20 (14.9) 13 (10.4) 17 (12.3)
Viral respiratory tract infection 10 (7.5) 11 (8.8) 11 (8.0)
Decreased PEF rate 6 (4.5) 9 (7.2) 8 (5.8)
Headache 9 (6.7) 7 (5.6) 2 (1.4)
Viral infection 7 (5.2) 5 (4.0) 6 (4.3)
Values are presented as numbers (percentages). A patient can be counted in more than 1 category. The treated set is shown.
AE, Adverse event; QD, once daily.
*Medical Dictionary for Regulatory Activities, version 16.1.
Includes asthma worsening and asthma exacerbations.
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LABAs versus long-acting anticholinergic bronchodilators have
not been reported but, if identified, might be of benefit in helping
to inform treatment decisions. Peters et al32 have suggested that a
positive response to albuterol (salbutamol) and a lower resting
heart rate can be used to predict a positive clinical response to tio-
tropium in adults with asthma; however, these results require
confirmation. Further prospective trials in adolescents with
poorly controlled asthma might help to identify predictors of
response to the different step-up options, including tiotropium.
In conclusion, in adolescent patientswithmoderate symptomatic
asthma, once-daily tiotropium added to at least ICS maintenance
treatment significantly improves lung function and demonstrates a
trend for improved asthma control and quality of life, with the
largest responses observed with the 5-mg dose. Tiotropium also
demonstrated safety and tolerability comparable with those of
placebo. These data are consistent with findings in adults and
support the addition of tiotropium Respimat in the treatment of
adolescent patients with moderate symptomatic asthma.
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Clinical implications: Once-daily tiotropium Respimat is an
effective add-on treatment to at least ICS maintenance therapy,
and its safety and tolerability are comparable with those of
placebo, in adolescents with moderate symptomatic asthma.REFERENCES
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FIG E1. Study design. Patients randomized to placebo received background ICS maintenance treatment
with or without an LTRA as active therapy only. In-clinic spirometric evaluations were conducted at baseline
(visit 2; randomization) and subsequently at visits 4, 6, and 8 in the evening. QD, Once daily.
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FIG E2. ACQ responder rate analyses: ACQ-6 score at week 24 (A), ACQ-6 score at week 48 (B), ACQ-7 score
at week 24 (C), and ACQ-7 score at week 48 (D). The full analysis set is shown. Common baselinemean ACQ-
6 score 6 SD is 2.0 6 0.5. ACQ-7 score 6 SD is 2.0 6 0.4. QD, Once daily.
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FIG E3. Weekly mean predose morning (A) and evening (B) PEF responses over 48 weeks. The full analysis
set is shown. Results are adjusted for treatment, country, week, baseline, treatment-by-week interaction,
and baseline-by-week interaction. Common baseline mean predose morning PEF 6 SD is 339.7 6 91.5 L/
min; common baseline mean predose evening PEF 6 SD is 359.9 6 91.1 L/min. Adjusted mean predose
morning and evening PEF response versus placebo is as follows: 5 mg of tiotropium, P 5 .02 and P 5 .01,
respectively, at week 24 and P 5 .005 and P 5 .008, respectively, at week 48; 2.5 mg of tiotropium, P 5 .17
and P 5 .08, respectively, at week 24 and P 5 .0504 and P 5 .03, respectively, at week 48. QD, Once daily.
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TABLE E1. Post hoc analysis of peak FEV1(0-3h) at week 24 by age group
Treatment Adjusted mean 6 SE (mL)
Active vs placebo Respimat
Adjusted mean of
difference 6 SE (mL) 95% CI P value
12-14 y
Tiotropium Respimat 5 mg QD (n 5 65) 570 6 48 139 6 66 10 to 268 .04
Tiotropium Respimat 2.5 mg QD (n 5 72) 584 6 46 154 6 64 27 to 280 .02
Placebo Respimat QD (n 5 76) 431 6 45
15-17 y
Tiotropium Respimat 5 mg QD (n 5 66) 596 6 54 211 6 78 58 to 365 .007
Tiotropium Respimat 2.5 mg QD (n 5 47) 506 6 64 121 6 85 247 to 289 .16
Placebo Respimat QD (n 5 61) 385 6 56
The full analysis set is shown. Results are adjusted for treatment, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Subgroup baseline mean FEV1 is
2452 mL for 12 to 14 years and 3101 mL for 15 to 17 years. Treatment-by-subgroup interaction P value 5 .21.
Peak FEV1(0-3h), Peak FEV1 within 3 hours after dosing; QD, once daily.
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TABLE E2. Post hoc analysis of trough FEV1 at week 24 by age group
Treatment Adjusted mean 6 SE (mL)
Active vs placebo Respimat
Adjusted mean of
difference 6 SE (mL) 95% CI P value
12-14 y
Tiotropium Respimat 5 mg QD (n 5 65) 410 6 51 103 6 70 235 to 240 .14
Tiotropium Respimat 2.5 mg QD (n 5 71) 416 6 49 109 6 68 225 to 243 .11
Placebo Respimat QD (n 5 76) 308 6 47
15-17 y
Tiotropium Respimat 5 mg QD (n 5 66) 425 6 59 125 6 85 242 to 292 .14
Tiotropium Respimat 2.5 mg QD (n 5 47) 360 6 70 60 6 94 2124 to 244 .52
Placebo Respimat QD (n 5 61) 299 6 61
The full analysis set is shown. Results are adjusted for treatment, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Subgroup baseline mean FEV1 is
2452 mL for 12 to 14 years and 3101 mL for 15 to 17 years. Treatment-by-subgroup interaction P value 5 .70.
QD, Once daily.
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TABLE E3. Secondary FVC efficacy end point responses at week 24
Treatment and parameter Adjusted mean 6 SE (mL)
Active vs placebo Respimat
Adjusted mean of
difference 6 SE (mL) 95% CI P value
Peak FVC(0-3h) (mL)
Tiotropium Respimat 5 mg QD (n 5 131) 403 6 43 72 6 56 237 to 182 .20
Tiotropium Respimat 2.5 mg QD (n 5 120) 419 6 45 88 6 57 224 to 200 .12
Placebo Respimat QD (n 5 137) 331 6 41
Trough FVC (mL)
Tiotropium Respimat 5 mg QD (n 5 131) 316 6 45 35 6 59 280 to 150 .55
Tiotropium Respimat 2.5 mg QD (n 5 119) 345 6 47 63 6 60 255 to 181 .29
Placebo Respimat QD (n 5 137) 281 6 43
FVC AUC(0-3h) (mL)
Tiotropium Respimat 5 mg QD (n 5 131) 311 6 40 71 6 53 232 to 175 .18
Tiotropium Respimat 2.5 mg QD (n 5 119) 330 6 42 90 6 54 216 to 196 .10
Placebo Respimat QD (n 5 137) 240 6 39
The full analysis set is shown. Results are adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Common baseline mean
FVC 6 SD is 3559 6 863 mL.
Peak FVC(0-3h), Peak FVC within 3 hours after dosing; QD, once daily.
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TABLE E4. Weekly mean rescue medication use over 48 weeks: weekly mean number of puffs of rescue medication during the
daytime, nighttime, and entire 24-hour period
Treatment and parameter Adjusted mean 6 SE
Active vs placebo Respimat
Adjusted mean of difference 6 SE 95% CI P value
Week 24
Daytime, no. of puffs
Tiotropium Respimat 5 mg QD (n 5 122) 20.215 6 0.068 20.009 6 0.090 20.186 to 0.168 .92
Tiotropium Respimat 2.5 mg QD (n 5 114) 20.209 6 0.071 20.003 6 0.092 20.184 to 0.178 .98
Placebo Respimat QD (n 5 132) 20.206 6 0.066
Nighttime, no. of puffs
Tiotropium Respimat 5 mg QD (n 5 124) 20.032 6 0.061 0.112 6 0.081 20.046 to 0.271 .17
Tiotropium Respimat 2.5 mg QD (n 5 110) 20.122 6 0.064 0.023 6 0.083 20.140 to 0.185 .79
Placebo Respimat QD (n 5 132) 20.144 6 0.059
24-h period, no. of puffs
Tiotropium Respimat 5 mg QD (n 5 125) 20.480 6 0.100 0.044 6 0.140 20.232 to 0.319 .76
Tiotropium Respimat 2.5 mg QD (n 5 117) 20.556 6 0.104 20.032 6 0.143 20.312 to 0.249 .83
Placebo Respimat QD (n 5 135) 20.524 6 0.098
Week 48
Daytime, no. of puffs
Tiotropium Respimat 5 mg QD (n 5 119) 20.246 6 0.068 20.115 6 0.091 20.294 to 0.064 .21
Tiotropium Respimat 2.5 mg QD (n 5 104) 20.229 6 0.073 20.098 6 0.094 20.283 to 0.086 .30
Placebo Respimat QD (n 5 124) 20.131 6 0.067
Nighttime, no. of puffs
Tiotropium Respimat 5 mg QD (n 5 114) 20.079 6 0.062 20.048 6 0.082 20.210 to 0.113 .56
Tiotropium Respimat 2.5 mg QD (n 5 105) 20.188 6 0.065 20.157 6 0.084 20.322 to 0.008 .06
Placebo Respimat QD (n 5 123) 20.031 6 0.060
24-h period, no. of puffs
Tiotropium Respimat 5 mg QD (n 5 123) 20.648 6 0.101 20.277 6 0.142 20.555 to 0.001 .051
Tiotropium Respimat 2.5 mg QD (n 5 108) 20.680 6 0.106 20.308 6 0.146 20.593 to 20.022 .04
Placebo Respimat QD (n 5 126) 20.372 6 0.099
The full analysis set is shown. Results are adjusted for treatment, week, baseline, treatment-by-week interaction, and baseline-by-week interaction. Common baseline mean 6 SD
is as follows: daytime 5 0.757 6 1.035; nighttime 5 0.596 6 0.894; and 24-hour period 5 1.268 6 1.739.
QD, Once daily.
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